Document is current
Any future updates will be listed below
-
Authors
Zeng, Weihong
Wang, Tiansheng
Stürmer, Til
He, Na
Shen, Peng
Lin, Hongbo
Guan, Xiaodong
Xu, Yang
-
Funding
Funding for this research was provided by:
American Diabetes Association (4-22-PDFPM-06)
National Natural Science Foundation of China (82304245)
Ministry of Science and Technology of the People's Republic of China (2021YFC2501300)
- License Information
-
More Information
Article History
Received: 6 January 2025
Accepted: 21 April 2025
First Online: 6 May 2025
<!--Emphasis Type='Bold' removed-->Declarations
:
: Ethics approval and consent to participate
: The study used only deidentified data and thus was deemed not to require informedconsent.
: WZ, TW, NH, PS, HL, XG, YX all have no conflicts of interest that are directly relevant to the content of this article or outside the submitted work. TS receives investigator-initiated research funding and support as Principal Investigator (R01AG056479) from the National Institute on Aging (NIA), and as Co-Investigator (R01CA277756) from the National Cancer Institute, National Institutes of Health (NIH). He also receives salary support as Director of Comparative Effectiveness Research (CER), NC TraCS Institute, UNC Clinical and Translational Science Award (UM1TR004406), co-Director of the Human Studies Consultation Core, NC Diabetes Research Center (P30DK124723), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the Center for Pharmacoepidemiology (current members: GlaxoSmithKline, UCB BioSciences, Takeda, AbbVie, Boehringer Ingelheim, Astellas, and Sarepta), and from a generous contribution from Dr. Nancy A. Dreyer to the Department of Epidemiology, University of North Carolina at Chapel Hill. Dr. Stürmer does not accept personal compensation of any kind from any pharmaceutical company. He owns stock in Novartis, Roche, and Novo Nordisk.
